In this article
Semax is a synthetic peptide derived from a fragment of ACTH, studied for neuroprotection and its influence on brain-derived neurotrophic factor (BDNF). Its human evidence is strongest in acute ischemic stroke, not in healthy cognition, and most trials were run in Russia. It is not FDA-approved in the United States and is treated as a research compound.
- Semax is a seven-amino-acid analog of ACTH(4-10), modified so it does not stimulate cortisol release.
- Preclinical work links it to higher BDNF expression, melanocortin receptor activity and less neuroinflammation.
- The best clinical data concern recovery after ischemic stroke; benefits for healthy cognition are not directly established.
- Signal IQ lists research doses of 250 to 500 mcg, one to three times daily, usually intranasal.
- It is typically studied in the nose, not by injection, and earlier-day timing is preferred.
What is Semax?
Semax was developed in the 1980s at Russia’s Institute of Molecular Genetics, originally to protect the brain from damage after ischemic stroke. It is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, built from a fragment of adrenocorticotropic hormone (ACTH).
The modification removed the part of ACTH that acts on the adrenal glands, so Semax does not stimulate cortisol production. The neurological activity was kept and is the focus of study.
Most research uses an intranasal preparation. The nasal route is thought to give access to the olfactory pathway and avoid some of the blood-brain barrier limits that affect peptides given elsewhere.
What the research shows
BDNF expression
BDNF supports neuron survival, new connections between neurons and long-term potentiation, a synaptic process behind learning and memory. Levels tend to fall with age, stress and poor sleep.
In rats, Semax increased BDNF mRNA in the hippocampus and frontal cortex. One study reported that a single dose produced a sustained rise that outlasted the peptide’s short half-life, which suggests it sets off a gene-expression response instead of acting as BDNF itself.
Ischemic stroke
This is the area with the most human data. A randomized controlled trial of intranasal Semax in the acute phase of ischemic stroke reported lower neurological deficit scores and better functional outcomes than control. Proposed explanations include less glutamate excitotoxicity, quieter inflammatory signaling and higher protective growth factors such as BDNF and NGF.
Neuroinflammation
Semax acts on melanocortin receptors, with MC4R and MC5R as the main targets in the central nervous system. In preclinical models it lowered pro-inflammatory cytokines such as IL-6 and TNF-alpha in brain tissue.
Stress response
Rodent studies under stress conditions reported a blunted cortisol response without sedation, consistent with the role of melanocortin receptors in regulating the HPA axis.
| Area | Evidence |
|---|---|
| BDNF upregulation | Preclinical (rodent) |
| Ischemic stroke recovery | Randomized trial in humans |
| Neuroinflammation | Preclinical |
| Stress reactivity | Preclinical |
| Focus, memory in healthy people | Anecdotal; not directly established |
Limits to keep in mind
The clinical base is thin by Western standards. Intranasal delivery is variable, and product quality strongly affects what a person actually receives. Response is also likely to differ with baseline BDNF, melanocortin receptor expression and overall brain health. Learn how to read a peptide COA to understand what testing can and cannot tell you.
Dosing ranges reported in research protocols
The Semax compound page on Signal IQ lists the following. These are descriptions of research use, not personal recommendations.
| Item | Reported range |
|---|---|
| Amount per dose | 250 to 500 mcg |
| Frequency | 1 to 3 times daily |
| Route | Most commonly intranasal |
| Timing | Earlier in the day; late dosing is generally avoided because of possible sleep disruption |
Duration is not firmly defined, and most community dosing is not based on large controlled trials. For general math and handling, see how to reconstitute peptides and how to store peptides.
Safety
Reported effects include mild headache, short-lived irritability, increased alertness, sleep disruption and mild nasal irritation with intranasal use. Long-term data are limited. Review peptide side effects and research use vs human use for context.
Related compounds
Semax is often discussed with Selank, Pinealon and Thymosin Alpha-1. Compare other options with peptides by goal, read the Semax research profile, or ask Pulse.
Frequently asked questions
Does Semax raise cortisol?
No. The ACTH fragment was modified to remove adrenal-stimulating activity, and some rodent work reports a blunted stress response.
Why is Semax usually intranasal?
The nasal route is thought to reach the brain through the olfactory pathway and sidestep the blood-brain barrier. Injectable use is discussed less and has no established dosing on Signal IQ.
Is Semax proven to improve focus or memory?
Not in healthy people. Reports of better focus and mental stamina are anecdotal, and the strongest human data involve stroke.
When is the best time of day to use it?
Research descriptions favor earlier in the day, since later dosing may disturb sleep in some people.
Is Semax approved by the FDA?
No. It is not approved in the United States and is considered a research compound.
How would someone judge their response?
Researchers emphasize a baseline first, such as sleep, subjective focus and stress markers, so any change can be compared rather than guessed.
References
- Gusev EI et al. — Randomized controlled trial of Semax in acute ischemic stroke, Cerebrovascular Diseases, 2005 — pubmed.ncbi.nlm.nih.gov
- Dolotov OV et al. — Semax stimulates BDNF expression in rat hippocampus, Neurochemical Research, 2006 — pubmed.ncbi.nlm.nih.gov
Go deeper on Signal IQ
Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.
Ask PulseEducational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.



